Home »

Search Result

Search Results for New

Links

Plumbing, Heating, and Air Conditioning Residential, Commercial, and Industrial Service, Remodel, and New Construction
Homeschool Library Builder is your resource for literature-based homeschooling! We offer thousands of discounted new and used living books and information on Literature based, Classical and Charlotte Mason homeschooling. We offer living books recommended
Light of Life is the story of Jesus the Christ edited by L. Lovett, with illustrations by Lovett and Old Masters. The Four Gospels and Acts are arranged in order of events with exciting easy-to-read stories true to Scripture. Continuing scenes paint with
Promise Checks turns ordinary check transactions into an opportunity to share your faith.
Show all results in links

Articles

This document defines the definition of "Christian" to be listed in this website!
Show all results in articles 

News

TAKING a business onto the global stage is hard. Doing it with banks can be suicidal owing to their complexity and leverage. For over 100 years an assortment of adventurers and visionaries have almost always tried one of two approaches. Either they spread firms thinly over scores of countries and focus on servicing big companies and facilitating trade. This is the way of Citigroup and HSBC, and the path that China's big lenders are racing down. Or they focus on investment banking from hubs; think of JPMorgan Chase or Deutsche Bank in New York, Hong Kong and London. Both blueprints have often resulted in buckets of tears.In the 1990s a “third way” emerged from provincial Spain; creating a global retail bank with a deep presence in many countries, allowing true economies of scale. The pioneer was Santander, a middle-weight bank from the Bay of Biscay. Today it is the king of the euro zone: the bloc's largest lender by market value, with 133m clients, mainly in Brazil, Britain, Mexico and...Continue reading
“IT'S always a lot of fun when you win,” President Donald Trump enthused after his tax package was approved by Congress in December. Company bosses nodded along. The centrepiece of the reform is a drastic cut to the corporate-tax rate, from 35% to 21%, taking it below the rich-country average. Although its impact is partly offset by some revenue-raising measures, the congressional Joint Committee on Taxation estimates that American business will gain around $330bn from the reform over the next ten years. Yet within that are sizeable variations in terms of which firms and industries benefit most.The biggest winners are more domestically oriented companies. These typically face higher effective tax rates than American companies with a big presence overseas, which do business in lower-tax countries. Bosses are also evaluating other new measures. So-called “full expensing”, for example, helps those with big spending plans by allowing them to deduct investment costs up front. But using debt will become less attractive, as interest payments are no longer fully deductible.Some firms experienced high volatility in their earnings for the final quarter of 2017 thanks to the treatment of so-called “deferred tax assets”. These are past tax losses carried forward to set against future tax bills, and such assets have shrunk in value because of the lower...Continue reading
WHEN Ken Frazier, chief executive of Merck, an American pharmaceutical giant, started his job in 2011, he had a hard decision to make. The firm had promising new drugs—such as Januvia, for diabetes, and Gardasil, a vaccine against cervical cancer. But the pharma industry was struggling with dismal returns on R&D and investors were questioning if companies were overspending on science. Some surrendered and started buying in drugs instead. But Mr Frazier opted to carry on backing his labs and promised publicly to spend on R&D for the long term, not for the stockmarket's immediate gratification.An opportunity to implement the pledge soon arrived. Merck's merger with another pharma firm, Schering-Plough, in 2009, had brought it an obscure new cancer drug. At first Merck's scientists were unimpressed and relegated the drug to a list of assets to be licensed out. There was widespread scepticism at the time about whether drugs that attacked cancer using the immune system would...Continue reading
Be honest, get help and know what you want in a new brand.
Weight loss, therapists and beauty products will always be in demand.
Show all results in news 
Familynet Topsites Independent Fundamental Baptist Topsites The Fundamental Top 500 Bible Top 1000 KJV Bible Top 500

Flag Counter